与临床使用的卡氮芥和顺铂相比，一种非交联铂-吖啶杂合剂在胶质母细胞瘤细胞中显示出更强的细胞毒性。
A non-crosslinking platinum-acridine hybrid agent shows enhanced cytotoxicity compared to clinical BCNU and cisplatin in glioblastoma cells.
作者信息
Hess Suzanne M, Anderson Joel G, Bierbach Ulrich
机构信息
Department of Radiation Oncology, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA.
出版信息
Bioorg Med Chem Lett. 2005 Jan 17;15(2):443-6. doi: 10.1016/j.bmcl.2004.10.049.
Using clonogenic survival assays, we demonstrated that a new platinum-acridine hybrid agent, PT-ACRAMTU, is cytotoxic in SNB19 and U87MG glioblastoma cells at low-micromolar concentrations. PT-ACRAMTU is more cytotoxic than ACRAMTU (the platinum-free acridine), acts in a time and dose dependent manner, and appears to generate an apoptotic response in both cell lines on the basis of increased caspase-3 activity.
通过克隆形成存活试验，我们证明了一种新型铂 - 吖啶杂交剂PT - ACRAMTU在低微摩尔浓度下对SNB19和U87MG胶质母细胞瘤细胞具有细胞毒性。PT - ACRAMTU比ACRAMTU（无铂吖啶）具有更强的细胞毒性，呈时间和剂量依赖性作用，并且基于半胱天冬酶 - 3活性的增加，在两种细胞系中似乎都引发了凋亡反应。
Zotero 插件